乳房生検用デバイス市場：2028年までの世界予測

Report Overview

The global breast biopsy devices market is projected to reach USD 2.6 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 10.0% from 2023 to 2028. The market growth is propelled by various factors, including the growing prevalence of breast cancer, the increasing implementation of breast cancer screening programs, favorable reimbursement settings, heightened awareness of early breast cancer detection, and rising demand for minimally invasive and non-invasive procedures. These factors are key drivers of market expansion, presenting significant business opportunities in the industry.

“The biopsy needles sub-segment to hold the largest share of the market in 2023.”

Based on type, the breast biopsy devices market is segmented into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other devices. The biopsy needles sub-segment held a major share of the market. The advantages offered by the substantial market dominance of this segment can be primarily attributed to the increasing occurrence of breast cancer and the rising rate of breast cancer diagnosis in emerging markets. Moreover, supportive government initiatives, such as the establishment of breast cancer screening programs and awareness campaigns, are anticipated to drive the adoption of breast biopsy procedures further.

“The therapy selection application segment is projected to register the highest growth during the forecast period.”
Based on application, the near breast biopsy market is broadly categorized into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The significant growth of the segment is attributed to the favorable reimbursement scenario and availability of advanced healthcare infrastructure. The emergence of precision medicine and personalized cancer treatment based on genetic analysis of tumor tissue over the past few decades has resulted in more specific treatment options which is further expected to influence the growth of the segment during the forecast period.

“The liquid breast biopsy segment is projected to register the highest CAGR during the forecast period.”
Based on procedure, the breast biopsy market is broadly categorized into needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. The substantial growth of this segment during the review period can be attributed to the approvals and launches of new products. Companies operating in the liquid breast biopsy market are actively investing in clinical trials and research through funding and grants, which will fuel further market expansion. These initiatives by industry players are expected to drive the growth of the liquid breast biopsy segment.

“The market in the North America region is expected to witness the highest growth during the forecast period.”
The breast biopsy market in the North America region is expected to hold a major share during the forecast period, primarily due to the high healthcare spending in the region and the rising prevalence of target diseases. Moreover, continuous advancements in technology, increasing incidence rates of breast cancer, favorable reimbursement conditions, and the implementation of new breast density notification laws in the US will further boost market growth.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

The prominent players in the breast biopsy devices market include Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (ITL), Becton Dickinson, and Company (US), Sterylab S.R.L ( Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Guardant Health, Inc. (US), NeoGenomics (US), Sysmex Inostics (Germany), Qiagen (Germany), Exact Sciences Corporation (US).

Research Coverage

This report studies the breast biopsy market based on type, procedure, technique, application, end-user, and geography. This study analyses the breast biopsy market. Additionally, it discusses the elements that influence market expansion, examines the opportunities and difficulties that exist in the sector, and gives information on the market’s competitive environment for market leaders. The research also examines the growth trends of micro-markets and projects the revenue of market segments for each of the five major regions (as well as the individual nations within each region).

Reasons to Buy the Report
The market leaders and new entrants will benefit from the report’s information on the revenue figures that are most closely approximated for the entire breast biopsy market and its subsegments. This study will assist stakeholders in comprehending the competitive environment and gaining deeper insights to better position their companies and develop appropriate go-to-market strategies. In addition, the research provides details on the major market drivers, constraints, challenges, and opportunities, assisting stakeholders in understanding the industry’s pulse.

This report provides insights on the following pointers:
• Analysis of key drivers (increasing incidence of breast cancer, increasing number of breast cancer screening programs, increasing demand for minimally invasive and non-invasive procedures, growing awareness regarding early detection of breast cancer, improved reimbursement scenario), restraints (risk of infections associated with the use of biopsy needles, stringent regulatory approval procedures product recalls), opportunities (emerging economies offer high growth potential, the emergence of liquid biopsy and promising clinical trials, increasing public–private investments and funding) and challenges (underdeveloped healthcare infrastructure and dearth of resources in developing countries).
• Product development/innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the breast biopsy market.
• Market development: comprehensive information about lucrative markets–the report analyses the breast biopsy market across varied regions.
• Market diversification: exhaustive information about new products, untapped geographies, recent developments, and investments in the breast biopsy market.
• Competitive assessment: in-depth assessment of market shares, growth strategies, and service offerings of leading players like Hologic Inc. (US), Becton Dickinson, and Company (US), Danaher Corporation (US), Argon Medical Devices(US), Merit Medical Systems (US), Menarini-Silicon Biosystems (ITL), Guardant Health, Inc. (US), NeoGenomics (US), Sysmex Inostics (Germany), Sterylab S.R.L ( Italy), Qiagen (Germany), and Biocept, Inc. (US).

Table of Contents

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 34
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 YEARS CONSIDERED 35
1.3.3 CURRENCY CONSIDERED 35
1.4 STAKEHOLDERS 35
1.5 SUMMARY OF CHANGES 36
1.5.1 RECESSION IMPACT 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
FIGURE 1 GLOBAL BREAST BIOPSY DEVICES MARKET: RESEARCH METHODOLOGY STEPS 39
FIGURE 2 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.1.1 Key data from secondary sources 41
2.1.2 PRIMARY DATA 42
FIGURE 3 BREAST BIOPSY DEVICES MARKET: BREAKDOWN OF PRIMARIES 43
2.1.2.1 Key data from primary sources 43
2.2 MARKET SIZE ESTIMATION 44
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 44
2.2.1 VENDOR REVENUE-BASED MARKET ESTIMATION 44
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 45
2.2.2 END-USER-BASED MARKET SIZE ESTIMATION 45
FIGURE 6 BREAST BIOPSY DEVICES MARKET: END-USER-BASED ESTIMATION 46
2.2.3 PRIMARY RESEARCH VALIDATION 46
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 7 DATA TRIANGULATION METHODOLOGY 47
2.4 RESEARCH LIMITATIONS 48
2.5 RISK ASSESSMENT 48
TABLE 1 BREAST BIOPSY DEVICES MARKET: RISK ASSESSMENT ANALYSIS 48
2.6 BREAST BIOPSY DEVICES MARKET: RECESSION IMPACT ANALYSIS 49
 
3 EXECUTIVE SUMMARY 50
FIGURE 8 BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 9 BREAST BIOPSY DEVICES MARKET SHARE, BY PROCEDURE, 2023 VS. 2028 51
FIGURE 10 BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 11 BREAST BIOPSY DEVICES MARKET SHARE, BY APPLICATION, 2023 VS. 2028 52
FIGURE 12 BREAST BIOPSY DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF BREAST BIOPSY DEVICES MARKET 54
4 PREMIUM INSIGHTS 55
4.1 BREAST BIOPSY DEVICES MARKET OVERVIEW 55
FIGURE 14 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET GROWTH 55
4.2 BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 56
FIGURE 15 ASSAY KITS TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 56
4.3 BREAST BIOPSY DEVICES MARKET, PROCEDURE, 2023 VS. 2028 (USD MILLION) 56
FIGURE 16 NEEDLE BREAST BIOPSY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 56
4.4 BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 17 IMAGE-GUIDED BIOPSY TO ACCOUNT FOR LARGEST SHARE OF BREAST BIOPSY DEVICES MARKET IN 2028 57
4.5 BREAST BIOPSY DEVICES MARKET, APPLICATION, 2023 VS. 2028 (USD MILLION) 58
FIGURE 18 EARLY CANCER SCREENING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58
4.6 BREAST BIOPSY DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 59
FIGURE 19 BREAST CARE CENTERS TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 59
4.7 BREAST BIOPSY DEVICES MARKET, BY REGION, 2021–2028 60
FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH IN MARKET DURING FORECAST PERIOD 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
FIGURE 21 BREAST BIOPSY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2.1 DRIVERS 62
5.2.1.1 Growing incidence of breast cancer 62
FIGURE 22 NUMBER OF BREAST CANCER CASES, BY COUNTRY, 2020 62
5.2.1.2 Increasing number of breast cancer screening programs 62
5.2.1.3 Increasing demand for minimally invasive and non-invasive procedures 63
5.2.1.4 Growing awareness of early detection of breast cancer 63
5.2.1.5 Improved reimbursement scenario 64
TABLE 2 MEDICARE REIMBURSEMENT FOR BREAST BIOPSY PROCEDURES 65
5.2.2 RESTRAINTS 66
5.2.2.1 Risk of infections associated with biopsy needles 66
5.2.2.2 Stringent regulatory approval procedures 66
5.2.2.3 Product recalls 67
TABLE 3 FDA-INITIATED PRODUCT RECALLS 67
5.2.3 OPPORTUNITIES 67
5.2.3.1 Growth potential in emerging economies 67
5.2.3.2 Emergence of liquid biopsy and promising clinical trials 68
TABLE 4 LIQUID BIOPSY CLINICAL TRIALS 68
5.2.3.3 Increasing public-private investments and funding 69
5.2.4 CHALLENGES 69
5.2.4.1 Shortage of skilled professionals and inadequate healthcare infrastructure 69
5.3 REGULATORY LANDSCAPE 70
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 8 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 9 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
5.3.2 REGULATORY ANALYSIS 72
5.3.2.1 North America 72
5.3.2.1.1 US 72
TABLE 10 US FDA-APPROVED BIOPSY DEVICES 72
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION 72
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 73
5.3.2.1.2 Canada 73
TABLE 13 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 73
5.3.2.2 Europe 74
5.3.2.3 Asia Pacific 74
5.3.2.3.1 Japan 74
TABLE 14 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 74
5.3.2.3.2 China 75
TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES 75
5.3.2.3.3 India 76
 
5.4 VALUE CHAIN ANALYSIS 77
5.4.1 RESEARCH & DEVELOPMENT 77
5.4.2 PROCUREMENT & PRODUCT DEVELOPMENT 77
5.4.3 MARKETING, SALES & DISTRIBUTION, AND POST-SALES SERVICES 77
FIGURE 23 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 77
5.5 SUPPLY CHAIN ANALYSIS 78
5.5.1 PROMINENT COMPANIES 78
5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES 78
5.5.3 END USERS 78
FIGURE 24 BREAST BIOPSY DEVICES MARKET: SUPPLY CHAIN ANALYSIS 78
5.6 ECOSYSTEM MARKET MAP 79
TABLE 16 BREAST BIOPSY DEVICES MARKET: ROLE IN ECOSYSTEM 79
5.7 TECHNOLOGY ANALYSIS 80
5.8 TRADE ANALYSIS 81
TABLE 17 IMPORT DATA FOR BIOPSY NEEDLES (HS CODE 90183240), BY COUNTRY, 2018–2022 (USD THOUSAND) 81
TABLE 18 EXPORT DATA FOR BREAST BIOPSY DEVICES (HS CODE 90183240), BY COUNTRY, 2018–2022 (USD THOUSAND) 81
TABLE 19 IMPORT DATA FOR MAMMOGRAPHY DEVICES (HS CODE 90221411), BY COUNTRY, 2018–2022 (USD THOUSAND) 82
TABLE 20 EXPORT DATA FOR MAMMOGRAPHY DEVICES (HS CODE 90221411), BY COUNTRY, 2018–2022 (USD THOUSAND) 82
5.9 PATENT ANALYSIS 83
FIGURE 25 PATENT DETAILS FOR BREAST BIOPSY (JANUARY 2012–JULY 2023) 83
5.10 PORTER’S FIVE FORCES ANALYSIS 84
TABLE 21 BREAST BIOPSY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 84
5.10.1 THREAT OF NEW ENTRANTS 84
5.10.2 THREAT OF SUBSTITUTES 84
5.10.3 BARGAINING POWER OF SUPPLIERS 84
5.10.4 BARGAINING POWER OF BUYERS 84
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.11 PRICING ANALYSIS 85
5.11.1 AVERAGE SELLING PRICE OF PRODUCTS, BY TYPE 85
TABLE 22 AVERAGE SELLING PRICE OF PRODUCTS (USD), 2022 85
5.11.2 AVERAGE SELLING PRICE TRENDS 86
5.12 CASE STUDY ANALYSIS 87
5.12.1 CASE STUDY 1: EVOLUTION OF WIRE LOCALIZATION TECHNIQUE 87
FIGURE 26 BREAST TUMOR LOCALIZATION: TECHNOLOGY EVOLUTION CHART 87
5.12.2 CASE STUDY 2: GROWING BREAST CARE FACILITIES IN US 89
5.13 KEY CONFERENCES & EVENTS, 2023–2025 90
TABLE 23 BREAST BIOPSY DEVICES MARKET: LIST OF MAJOR CONFERENCES & EVENTS (2023–2025) 90
 
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.14.1 KEY STAKEHOLDERS & BUYING CRITERIA 92
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BREAST BIOPSY DEVICES 92
5.14.2 BUYING CRITERIA 92
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BREAST BIOPSY DEVICES 92
FIGURE 28 KEY BUYING CRITERIA FOR BREAST BIOPSY DEVICES 93
TABLE 25 KEY BUYING CRITERIA FOR BREAST BIOPSY DEVICES 93
6 BREAST BIOPSY DEVICES MARKET, BY TYPE 94
6.1 INTRODUCTION 95
TABLE 26 BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 95
TABLE 27 BREAST BIOPSY DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 95
6.2 BIOPSY NEEDLES 96
6.2.1 TECHNOLOGICAL ADVANCEMENTS IN BIOPSY NEEDLES TO DRIVE MARKET GROWTH 96
TABLE 28 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 29 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY TYPE, 2021–2028 (USD MILLION) 97
TABLE 30 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY TECHNIQUE, 2021–2028 (USD MILLION) 97
TABLE 31 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 32 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY END USER, 2021–2028 (USD MILLION) 98
6.3 GUIDANCE SYSTEMS 98
6.3.1 PROCEDURAL ADVANTAGES OF GUIDED BIOPSIES TO FUEL GROWTH 98
TABLE 33 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 34 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2021–2028 (USD MILLION) 99
TABLE 35 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TECHNIQUE, 2021–2028 (USD MILLION) 100
TABLE 36 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY APPLICATION, 2021–2028 (USD MILLION) 100
TABLE 37 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY END USER, 2021–2028 (USD MILLION) 101
6.4 BIOPSY TABLES 101
6.4.1 GROWING USE OF BIOPSY TABLES TO PERFORM STEREOTACTIC BIOPSY PROCEDURES TO FAVOR MARKET GROWTH 101
TABLE 38 BREAST BIOPSY DEVICES MARKET FOR BIOPSY TABLES, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 39 BREAST BIOPSY DEVICES MARKET FOR BIOPSY TABLES, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 40 BREAST BIOPSY DEVICES MARKET FOR BIOPSY TABLES, BY TECHNIQUE, 2021–2028 (USD MILLION) 103
TABLE 41 BREAST BIOPSY DEVICES MARKET FOR BIOPSY TABLES, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 42 BREAST BIOPSY DEVICES MARKET FOR BIOPSY TABLES, BY END USER, 2021–2028 (USD MILLION) 104
6.5 ASSAY KITS 104
6.5.1 PRODUCT APPROVALS AND LAUNCHES TO DRIVE SEGMENTAL GROWTH 104
TABLE 43 BREAST BIOPSY DEVICES MARKET FOR ASSAY KITS, BY REGION, 2021–2028 (USD MILLION) 105
TABLE 44 BREAST BIOPSY DEVICES MARKET FOR ASSAY KITS, BY TYPE, 2021–2028 (USD MILLION) 105
TABLE 45 BREAST BIOPSY DEVICES MARKET FOR ASSAY KITS, BY TECHNIQUE, 2021–2028 (USD MILLION) 106
TABLE 46 BREAST BIOPSY DEVICES MARKET FOR ASSAY KITS, BY APPLICATION, 2021–2028 (USD MILLION) 106
TABLE 47 BREAST BIOPSY DEVICES MARKET FOR ASSAY KITS, BY END USER, 2021–2028 (USD MILLION) 107
6.6 LIQUID BIOPSY INSTRUMENTS 107
6.6.1 ONGOING RESEARCH AND CLINICAL TRIALS TO DELIVER NOVEL SOLUTIONS IN MARKET 107
TABLE 48 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 49 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 50 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY INSTRUMENTS, BY TECHNIQUE, 2021–2028 (USD MILLION) 109
TABLE 51 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY INSTRUMENTS, BY APPLICATION, 2021–2028 (USD MILLION) 109
TABLE 52 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY INSTRUMENTS, BY END USER, 2021–2028 (USD MILLION) 110
6.7 LOCALIZATION WIRES 110
6.7.1 WIDE USAGE OF LOCALIZATION WIRES TO LOCATE BREAST ABNORMALITIES AND LUMPS TO BOOST MARKET 110
TABLE 53 BREAST BIOPSY DEVICES MARKET FOR LOCALIZATION WIRES, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 54 BREAST BIOPSY DEVICES MARKET FOR LOCALIZATION WIRES, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 55 BREAST BIOPSY DEVICES MARKET FOR LOCALIZATION WIRES, BY TECHNIQUE, 2021–2028 (USD MILLION) 112
TABLE 56 BREAST BIOPSY DEVICES MARKET FOR LOCALIZATION WIRES, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 57 BREAST BIOPSY DEVICES MARKET FOR LOCALIZATION WIRES, BY END USER, 2021–2028 (USD MILLION) 113
6.8 OTHER DEVICES 113
TABLE 58 OTHER BREAST BIOPSY DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 59 OTHER BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 60 OTHER BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 114
TABLE 61 OTHER BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 62 OTHER BREAST BIOPSY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 115
7 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE 116
7.1 INTRODUCTION 117
TABLE 63 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2021–2028 (USD MILLION) 117
7.2 NEEDLE BREAST BIOPSY 117
TABLE 64 BREAST BIOPSY DEVICES MARKET FOR NEEDLE BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 118
7.2.1 CORE-NEEDLE BIOPSY 118
7.2.1.1 Procedural advantages of guidance system-based biopsy to drive revenue growth 118
TABLE 65 BREAST BIOPSY DEVICES MARKET FOR CORE-NEEDLE BIOPSY, BY REGION, 2021–2028 (USD MILLION) 119
7.2.2 VACUUM-ASSISTED BIOPSY 119
7.2.2.1 High diagnostic specificity and accuracy of technique to boost demand 119
TABLE 66 BREAST BIOPSY DEVICES MARKET FOR VACUUM-ASSISTED BIOPSY, BY REGION, 2021–2028 (USD MILLION) 120
7.2.3 FINE-NEEDLE ASPIRATION BIOPSY 120
7.2.3.1 Drawbacks associated with procedure to limit market growth 120
TABLE 67 BREAST BIOPSY DEVICES MARKET FOR FINE-NEEDLE ASPIRATION BIOPSY, BY REGION, 2021–2028 (USD MILLION) 121
7.3 OPEN SURGICAL BREAST BIOPSY 121
TABLE 68 BREAST BIOPSY DEVICES MARKET FOR OPEN SURGICAL BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 121
7.3.1 EXCISIONAL BIOPSY 122
7.3.1.1 Risk of postoperative complications to hinder market growth 122
TABLE 69 BREAST BIOPSY DEVICES MARKET FOR EXCISIONAL BIOPSY, BY REGION, 2021–2028 (USD MILLION) 122
7.3.2 INCISIONAL BIOPSY 122
7.3.2.1 Longer recovery period associated with incisional biopsy to restrict growth 122
TABLE 70 BREAST BIOPSY DEVICES MARKET FOR INCISIONAL BIOPSY, BY REGION, 2021–2028 (USD MILLION) 123
7.4 LIQUID BREAST BIOPSY 123
TABLE 71 BREAST BIOPSY DEVICES MARKET FOR LIQUID BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 123
7.4.1 CIRCULATING TUMOR CELLS 124
7.4.1.1 Ability to provide important information on molecular properties of breast tumors to boost market 124
TABLE 72 BREAST BIOPSY DEVICES MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2021–2028 (USD MILLION) 124
7.4.2 CIRCULATING TUMOR DNA 125
7.4.2.1 Low concentrations of ctDNA to pose challenges in screening mutations 125
TABLE 73 BREAST BIOPSY DEVICES MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2021–2028 (USD MILLION) 125
7.4.3 OTHER BIOMARKERS 126
TABLE 74 BREAST BIOPSY DEVICES MARKET FOR OTHER BIOMARKERS, BY REGION, 2021–2028 (USD MILLION) 126
8 BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE 127
8.1 INTRODUCTION 128
TABLE 75 BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 128
8.2 IMAGE-GUIDED BIOPSY 128
TABLE 76 BREAST BIOPSY DEVICES MARKET FOR IMAGE-GUIDED BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 129
8.2.1 MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY 129
8.2.1.1 Increasing number of government-initiated breast screening programs to drive segmental growth 129
TABLE 77 BREAST BIOPSY DEVICES MARKET FOR MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY, BY REGION, 2021–2028 (USD MILLION) 130
8.2.2 ULTRASOUND-GUIDED BIOPSY 130
8.2.2.1 Advantages of technique to boost adoption in coming years 130
TABLE 78 BREAST BIOPSY DEVICES MARKET FOR ULTRASOUND-GUIDED BIOPSY, BY REGION, 2021–2028 (USD MILLION) 130
8.2.3 MRI-GUIDED BIOPSY 131
8.2.3.1 High cost and low specificity to affect demand 131
TABLE 79 BREAST BIOPSY DEVICES MARKET FOR MRI-GUIDED BIOPSY, BY REGION, 2021–2028 (USD MILLION) 131
8.3 LIQUID BIOPSY 131
TABLE 80 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 132
8.3.1 PCR-BASED BIOPSY 132
8.3.1.1 Continuous advancements in PCR technology to propel growth 132
TABLE 81 BREAST BIOPSY DEVICES MARKET FOR PCR-BASED BIOPSY, BY REGION, 2021–2028 (USD MILLION) 132
8.3.2 NGS-BASED BIOPSY 133
8.3.2.1 Technological advancements and advantages to drive growth 133
TABLE 82 NGS-BASED TECHNOLOGIES FOR ONCOLOGY APPLICATIONS 133
TABLE 83 BREAST BIOPSY DEVICES MARKET FOR NGS-BASED BIOPSY, BY REGION, 2021–2028 (USD MILLION) 134
8.3.3 MICROARRAY-BASED BIOPSY 134
8.3.3.1 Ongoing research and promising results to drive market growth 134
TABLE 84 BREAST BIOPSY DEVICES MARKET FOR MICROARRAY-BASED BIOPSY, BY REGION, 2021–2028 (USD MILLION) 135
8.4 OTHER TECHNIQUES 135
TABLE 85 BREAST BIOPSY DEVICES MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION) 136
9 BREAST BIOPSY DEVICES MARKET, BY APPLICATION 137
9.1 INTRODUCTION 138
TABLE 86 BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
9.2 EARLY CANCER SCREENING 138
9.2.1 GROWING AWARENESS ABOUT EARLY CANCER DETECTION TO DRIVE MARKET GROWTH 138
TABLE 87 BREAST BIOPSY DEVICES MARKET FOR EARLY CANCER SCREENING, BY REGION, 2021–2028 (USD MILLION) 139
9.3 THERAPY SELECTION 139
9.3.1 EMERGENCE OF PLASMA-BASED GENOTYPING TO DRIVE GROWTH IN DEVELOPED COUNTRIES 139
TABLE 88 BREAST BIOPSY DEVICES MARKET FOR THERAPY SELECTION, BY REGION, 2021–2028 (USD MILLION) 140
9.4 TREATMENT MONITORING 140
9.4.1 GROWING DEMAND FOR LIQUID BIOPSY FOR REAL-TIME TREATMENT MONITORING TO BOOST MARKET 140
TABLE 89 BREAST BIOPSY DEVICES MARKET FOR TREATMENT MONITORING, BY REGION, 2021–2028 (USD MILLION) 141
9.5 RECURRENCE MONITORING 141
9.5.1 UNMET CLINICAL NEEDS TO CREATE OPPORTUNITIES FOR PLAYERS 141
TABLE 90 BREAST BIOPSY DEVICES MARKET FOR RECURRENCE MONITORING, BY REGION, 2021–2028 (USD MILLION) 142
10 BREAST BIOPSY DEVICES MARKET, BY END USER 143
10.1 INTRODUCTION 144
TABLE 91 BREAST BIOPSY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.2 HOSPITALS & SURGICAL CENTERS 144
10.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO BOOST MARKET 144
TABLE 92 BREAST BIOPSY DEVICES MARKET FOR HOSPITALS & SURGICAL CENTERS, BY REGION, 2021–2028 (USD MILLION) 145
10.3 BREAST CARE CENTERS 145
10.3.1 GROWING POPULARITY OF BREAST CARE CENTERS IN DEVELOPED COUNTRIES TO FUEL GROWTH 145
TABLE 93 BREAST BIOPSY DEVICES MARKET FOR BREAST CARE CENTERS, BY REGION, 2021–2028 (USD MILLION) 146
10.4 IMAGING CLINICS & DIAGNOSTIC CENTERS 146
10.4.1 RISING NUMBER OF PRIVATE IMAGING CENTERS TO CONTRIBUTE TO MARKET GROWTH 146
TABLE 94 BREAST BIOPSY DEVICES MARKET FOR IMAGING CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2021–2028 (USD MILLION) 147
11 BREAST BIOPSY DEVICES MARKET, BY REGION 148
11.1 INTRODUCTION 149
TABLE 95 BREAST BIOPSY DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 149
11.2 NORTH AMERICA 149
FIGURE 29 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET SNAPSHOT 150
11.2.1 NORTH AMERICA: RECESSION IMPACT 150
TABLE 96 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 97 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 98 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2021–2028 (USD MILLION) 152
TABLE 99 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR NEEDLE BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 100 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR OPEN SURGICAL BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 101 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR LIQUID BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 102 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153
TABLE 103 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 154
TABLE 104 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR IMAGE-GUIDED BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 105 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 106 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 155
11.2.2 US 155
11.2.2.1 US to dominate North American breast biopsy devices market during forecast period 155
TABLE 107 US: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
11.2.3 CANADA 156
11.2.3.1 Growing incidence of breast cancer and favorable government guidelines to support market growth 156
TABLE 108 CANADA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
11.3 EUROPE 157
11.3.1 EUROPE: RECESSION IMPACT 158
TABLE 109 EUROPE: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 110 EUROPE: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 111 EUROPE: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2021–2028 (USD MILLION) 159
TABLE 112 EUROPE: BREAST BIOPSY DEVICES MARKET FOR NEEDLE BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 113 EUROPE: BREAST BIOPSY DEVICES MARKET FOR OPEN SURGICAL BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 114 EUROPE: BREAST BIOPSY DEVICES MARKET FOR LIQUID BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 115 EUROPE: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 116 EUROPE: BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 161
TABLE 117 EUROPE: BREAST BIOPSY DEVICES MARKET FOR IMAGE-GUIDED BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 118 EUROPE: BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 119 EUROPE: BREAST BIOPSY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 163
11.3.2 GERMANY 163
11.3.2.1 Favorable changes in reimbursement scenario to fuel adoption of technologically advanced products 163
TABLE 120 GERMANY: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
11.3.3 UK 164
11.3.3.1 Initiatives by public & private organizations to increase awareness about breast cancer 164
TABLE 121 UK: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
11.3.4 FRANCE 165
11.3.4.1 Rising geriatric population to support market growth 165
TABLE 122 FRANCE: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
11.3.5 ITALY 166
11.3.5.1 Evolving regulatory scenario for breast biopsy to boost market 166
TABLE 123 ITALY: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 167
11.3.6 SPAIN 167
11.3.6.1 Government focus on early and effective breast cancer diagnosis to favor market growth 167
TABLE 124 SPAIN: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
11.3.7 REST OF EUROPE 168
TABLE 125 REST OF EUROPE: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
11.4 ASIA PACIFIC 169
FIGURE 30 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET SNAPSHOT 170
11.4.1 ASIA PACIFIC: RECESSION IMPACT 170
TABLE 126 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 127 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 128 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2021–2028 (USD MILLION) 172
TABLE 129 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR NEEDLE BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 130 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR OPEN SURGICAL BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 131 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR LIQUID BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 132 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 133 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 174
TABLE 134 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR IMAGE-GUIDED BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 135 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 136 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 175
11.4.2 CHINA 175
11.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth 175
TABLE 137 CHINA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
11.4.3 JAPAN 176
11.4.3.1 Presence of universal healthcare reimbursement scenario to support growth 176
TABLE 138 JAPAN: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
11.4.4 INDIA 177
11.4.4.1 Government initiatives to improve female health to drive market growth in India 177
TABLE 139 INDIA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
11.4.5 AUSTRALIA 178
11.4.5.1 Rising research investments and awareness campaigns to fuel growth 178
TABLE 140 AUSTRALIA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
11.4.6 SOUTH KOREA 179
11.4.6.1 Rising R&D and promising clinical trials to positively impact market growth 179
TABLE 141 SOUTH KOREA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
11.4.7 REST OF ASIA PACIFIC 180
TABLE 142 REST OF ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
11.5 LATIN AMERICA 181
11.5.1 LATIN AMERICA: RECESSION IMPACT 182
TABLE 143 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 144 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 145 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2021–2028 (USD MILLION) 183
TABLE 146 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR NEEDLE BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 147 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR OPEN SURGICAL BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 148 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR LIQUID BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 149 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 150 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 185
TABLE 151 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR IMAGE-GUIDED BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 152 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 153 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 187
11.5.2 BRAZIL 187
11.5.2.1 Brazil to dominate Latin American market during forecast period 187
TABLE 154 BRAZIL: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 188
11.5.3 MEXICO 188
11.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth 188
TABLE 155 MEXICO: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
11.5.4 REST OF LATIN AMERICA 189
TABLE 156 REST OF LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
11.5.5 MIDDLE EAST & AFRICA 190
11.5.5.1 Improving healthcare infrastructure and increasing public-private investments to drive market 190
11.5.6 MIDDLE EAST & AFRICA: RECESSION IMPACT 191
TABLE 157 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 158 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2021–2028 (USD MILLION) 192
TABLE 159 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR NEEDLE BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 160 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR OPEN SURGICAL BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 161 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR LIQUID BREAST BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 162 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 194
TABLE 163 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 194
TABLE 164 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR IMAGE-GUIDED BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 165 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 166 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 196
12 COMPETITIVE LANDSCAPE 197
12.1 INTRODUCTION 197
FIGURE 31 KEY DEVELOPMENTS BY LEADING PLAYERS IN BREAST BIOPSY DEVICES MARKET, JANUARY 2020–FEBRUARY 2022 197
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 198
12.3 REVENUE SHARE ANALYSIS 198
FIGURE 32 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS 198
12.4 MARKET SHARE ANALYSIS 199
FIGURE 33 BREAST BIOPSY DEVICES MARKET SHARE, BY KEY PLAYER (2022) 199
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 200
12.5.1 STARS 201
12.5.2 EMERGING LEADERS 201
12.5.3 PERVASIVE PLAYERS 201
12.5.4 PARTICIPANTS 201
FIGURE 34 BREAST BIOPSY DEVICES MARKET: COMPANY EVALUATION MATRIX (2022) 202
12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 203
12.6.1 PROGRESSIVE COMPANIES 203
12.6.2 RESPONSIVE COMPANIES 203
12.6.3 DYNAMIC COMPANIES 203
12.6.4 STARTING BLOCKS 203
FIGURE 35 BREAST BIOPSY DEVICES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 204
12.7 COMPETITIVE BENCHMARKING 205
TABLE 167 BREAST BIOPSY DEVICES MARKET: COMPETITIVE BENCHMARKING 205
12.8 COMPANY FOOTPRINT ANALYSIS 206
TABLE 168 BREAST BIOPSY DEVICES MARKET: REGIONAL FOOTPRINT ANALYSIS 206
12.9 COMPETITIVE SCENARIO 207
12.9.1 PRODUCT LAUNCHES & APPROVALS 207
12.9.2 DEALS 208
13 COMPANY PROFILES 210
13.1 KEY PLAYERS 210
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 HOLOGIC, INC. 210
TABLE 169 HOLOGIC, INC.: BUSINESS OVERVIEW 210
FIGURE 36 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 211
TABLE 170 HOLOGIC, INC.: PRODUCT LAUNCHES & APPROVALS 212
TABLE 171 HOLOGIC, INC.: DEALS 212
13.1.2 DANAHER CORPORATION 214
TABLE 172 DANAHER CORPORATION: BUSINESS OVERVIEW 214
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 215
TABLE 173 DANAHER CORPORATION: PRODUCT LAUNCHES 216
13.1.3 BECTON, DICKINSON AND COMPANY 217
TABLE 174 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 217
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 218
TABLE 175 BECTON, DICKINSON AND COMPANY: EXPANSIONS 219
13.1.4 QIAGEN 221
TABLE 176 QIAGEN: BUSINESS OVERVIEW 221
FIGURE 39 QIAGEN: COMPANY SNAPSHOT (2022) 222
TABLE 177 QIAGEN: PRODUCT LAUNCHES 223
13.1.5 F. HOFFMANN-LA ROCHE LTD. 224
TABLE 178 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 224
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 225
13.1.6 ARGON MEDICAL DEVICES 227
TABLE 179 ARGON MEDICAL DEVICES: BUSINESS OVERVIEW 227
TABLE 180 ARGON MEDICAL DEVICES: PRODUCT LAUNCHES 228
TABLE 181 ARGON MEDICAL DEVICES: DEALS 229
13.1.7 MERIT MEDICAL SYSTEMS 230
TABLE 182 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW 230
FIGURE 41 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2022) 231
TABLE 183 MERIT MEDICAL SYSTEMS: PRODUCT LAUNCHES & APPROVALS 233
TABLE 184 MERIT MEDICAL SYSTEMS: DEALS 233
13.1.8 MENARINI SILICON BIOSYSTEMS SPA 234
TABLE 185 MENARINI SILICON BIOSYSTEMS: BUSINESS OVERVIEW 234
TABLE 186 MENARINI SILICON BIOSYSTEMS: PRODUCT LAUNCHES 235
TABLE 187 MENARINI SILICON BIOSYSTEMS: DEALS 235
13.1.9 GUARDANT HEALTH, INC. 236
TABLE 188 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW 236
FIGURE 42 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2022) 237
TABLE 189 GUARDANT HEALTH, INC.: DEALS 238
13.1.10 NEOGENOMICS LABORATORIES, INC. 239
TABLE 190 NEOGENOMICS LABORATORIES, INC.: BUSINESS OVERVIEW 239
FIGURE 43 NEOGENOMICS LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 239
TABLE 191 NEOGENOMICS LABORATORIES, INC.: PRODUCT LAUNCHES 240
TABLE 192 NEOGENOMICS LABORATORIES, INC.: DEALS 240
13.1.11 STERYLAB S.R.L 241
TABLE 193 STERYLAB S.R.L: BUSINESS OVERVIEW 241
13.1.12 BIOCEPT, INC. 242
TABLE 194 BIOCEPT, INC.: BUSINESS OVERVIEW 242
13.1.13 BIO-RAD LABORATORIES, INC. 243
TABLE 195 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 243
FIGURE 44 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 244
13.1.14 EXACT SCIENCES CORPORATION 245
TABLE 196 EXACT SCIENCES CORPORATION: BUSINESS OVERVIEW 245
FIGURE 45 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2022) 246
TABLE 197 EXACT SCIENCES CORPORATION: DEALS 247
13.1.15 SYSMEX INOSTICS, INC. (A SUBSIDIARY OF SYSMEX CORPORATION) 248
TABLE 198 SYSMEX INOSTICS: BUSINESS OVERVIEW 248
FIGURE 46 SYSMEX INOSTICS: COMPANY SNAPSHOT (2022) 249
TABLE 199 SYSMEX INOSTICS: DEALS 250
13.2 OTHER PLAYERS 251
13.2.1 THERMO FISHER SCIENTIFIC 251
13.2.2 CARDIFF ONCOLOGY INC. 251
13.2.3 MYRIAD GENETICS, INC. 252
13.2.4 ILLUMINA, INC. 252
13.2.5 FLUXION BIOSCIENCES, INC. 253
13.2.6 FUJIFILM HOLDINGS CORPORATION 254
13.2.7 INRAD, INC. 255
13.2.8 IZI MEDICAL PRODUCTS 256
13.2.9 REMINGTON MEDICAL INC. 257
13.2.10 CP MEDICAL 258
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 259
14.1 DISCUSSION GUIDE 259
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 264
14.3 CUSTOMIZATION OPTIONS 266
14.4 RELATED REPORTS 267
14.5 AUTHOR DETAILS 268